1. males currently receiving estrogen-based hormonal therapy. 2. current participation in another interventional clinical trial. 3. ventilated and/or in icu. 4. any unexplained abnormal bleeding including, but not limited to, vaginal bleeding. 5. diagnosed protein c, protein s or antithrombin iii deficiency or any other known inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia, anti-phospholipid antibodies). 6. renal impairment (glomerular filtration rate \[gfr\] \<30 ml/min/1.73 m²). 7. presence or history of severe liver disease or liver cancer (non-malignant or malignant). 8. presence or history (including suspected diagnosis) of breast cancer. 9. presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g. endometrial cancer). 10. patients with endometrial hyperplasia. 11. patients with severe hypoxemia at risk of endotracheal intubation. 12. immunocompromised patients 13. history of stroke, acute coronary syndromes, or angina pectoris. 14. presence or history of arterial or venous thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli). 15. patients with any condition, including findings in the patients' medical history or in the screening study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation, including patients with suspected genital cancer or suspected breast cancer and patients with increased risk of development of venous thrombosis/thromboembolia for reasons other than covid-19 disease. 16. use of zanamivir or oseltamivir within 1 week prior to randomization. 17. patients who have received prior investigational or off-label agents for covid-19. (note: use of antivirals and corticosteroids is allowed if part of standard of care). 18. using methyldopa or clonidine containing antihypertensive medication. 19. hypersensitivity to the active substance of the study drug or any other components of the study drug.

1. males currently receiving estrogen-based hormonal therapy. 2. current participation in another interventional clinical trial. 3. ventilated and/or in icu. 4. any unexplained abnormal bleeding including, but not limited to, vaginal bleeding. 5. diagnosed protein c, protein s or antithrombin iii deficiency or any other known inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia, anti-phospholipid antibodies). 6. renal impairment (glomerular filtration rate \[gfr\] \<30 ml/min/1.73 m²). 7. presence or history of severe liver disease or liver cancer (non-malignant or malignant). 8. presence or history (including suspected diagnosis) of breast cancer. 9. presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g. endometrial cancer). 10. patients with endometrial hyperplasia. 11. patients with severe hypoxemia at risk of endotracheal intubation. 12. immunocompromised patients 13. history of stroke, acute coronary syndromes, or angina pectoris. 14. presence or history of arterial or venous thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli). 15. patients with any condition, including findings in the patients' medical history or in the screening study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation, including patients with suspected genital cancer or suspected breast cancer and patients with increased risk of development of venous thrombosis/thromboembolia for reasons other than covid-19 disease. 16. use of zanamivir or oseltamivir within 1 week prior to randomization. 17. patients who have received prior investigational or off-label agents for covid-19. (note: use of antivirals and corticosteroids is allowed if part of standard of care). 18. using methyldopa or clonidine containing antihypertensive medication. 19. hypersensitivity to the active substance of the study drug or any other components of the study drug.

males currently receiving estrogen-based hormonal therapy. current participation in another interventional clinical trial. ventilated and/or in icu. any unexplained abnormal bleeding including, but not limited to, vaginal bleeding. diagnosed protein c, protein s or antithrombin iii deficiency or any other known inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia, anti-phospholipid antibodies). renal impairment (glomerular filtration rate [gfr] <30 ml/min/1.73 m²). presence or history of severe liver disease or liver cancer (non-malignant or malignant). presence or history (including suspected diagnosis) of breast cancer. presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g. endometrial cancer). patients with endometrial hyperplasia. patients with severe hypoxemia at risk of endotracheal intubation. immunocompromised patients history of stroke, acute coronary syndromes, or angina pectoris. presence or history of arterial or venous thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli). patients with any condition, including findings in the patients' medical history or in the screening study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation, including patients with suspected genital cancer or suspected breast cancer and patients with increased risk of development of venous thrombosis/thromboembolia for reasons other than covid-19 disease. use of zanamivir or oseltamivir within 1 week prior to randomization. patients who have received prior investigational or off-label agents for covid-19. (note: use of antivirals and corticosteroids is allowed if part of standard of care). using methyldopa or clonidine containing antihypertensive medication. hypersensitivity to the active substance of the study drug or any other components of the study drug.

males currently receiving estrogen-based hormonal therapy. current participation in another interventional clinical trial. ventilated and/or in icu. any unexplained abnormal bleeding including, but not limited to, vaginal bleeding. diagnosed protein c, protein s or antithrombin iii deficiency or any other known inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia, anti-phospholipid antibodies). renal impairment (glomerular filtration rate [gfr] <30 ml/min/1.73 m²). presence or history of severe liver disease or liver cancer (non-malignant or malignant). presence or history (including suspected diagnosis) of breast cancer. presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g. endometrial cancer). patients with endometrial hyperplasia. patients with severe hypoxemia at risk of endotracheal intubation. immunocompromised patients history of stroke, acute coronary syndromes, or angina pectoris. presence or history of arterial or venous thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli). patients with any condition, including findings in the patients' medical history or in the screening study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation, including patients with suspected genital cancer or suspected breast cancer and patients with increased risk of development of venous thrombosis/thromboembolia for reasons other than covid-19 disease. use of zanamivir or oseltamivir within 1 week prior to randomization. patients who have received prior investigational or off-label agents for covid-19. (note: use of antivirals and corticosteroids is allowed if part of standard of care). using methyldopa or clonidine containing antihypertensive medication. hypersensitivity to the active substance of the study drug or any other components of the study drug.

1. males currently receiving estrogen-based hormonal therapy. 2. current participation in another interventional clinical trial. 3. ventilated and/or in icu. 4. any unexplained abnormal bleeding including, but not limited to, vaginal bleeding. 5. diagnosed protein c, protein s or antithrombin iii deficiency or any other known inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia, anti-phospholipid antibodies). 6. renal impairment (glomerular filtration rate [gfr] <30 ml/min/1.73 m²). 7. presence or history of severe liver disease or liver cancer (non-malignant or malignant). 8. presence or history (including suspected diagnosis) of breast cancer. 9. presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g. endometrial cancer). 10. patients with endometrial hyperplasia. 11. patients with severe hypoxemia at risk of endotracheal intubation. 12. immunocompromised patients 13. history of stroke, acute coronary syndromes, or angina pectoris. 14. presence or history of arterial or venous thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli). 15. patients with any condition, including findings in the patients' medical history or in the screening study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation, including patients with suspected genital cancer or suspected breast cancer and patients with increased risk of development of venous thrombosis/thromboembolia for reasons other than covid-19 disease. 16. use of zanamivir or oseltamivir within 1 week prior to randomization. 17. patients who have received prior investigational or off-label agents for covid-19. (note: use of antivirals and corticosteroids is allowed if part of standard of care). 18. using methyldopa or clonidine containing antihypertensive medication. 19. hypersensitivity to the active substance of the study drug or any other components of the study drug.

1. males currently receiving estrogen-based hormonal therapy. 2. current participation in another interventional clinical trial. 3. ventilated and/or in icu. 4. any unexplained abnormal bleeding including, but not limited to, vaginal bleeding. 5. diagnosed protein c, protein s or antithrombin iii deficiency or any other known inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia, anti-phospholipid antibodies). 6. renal impairment (glomerular filtration rate [gfr] <30 ml/min/1.73 m²). 7. presence or history of severe liver disease or liver cancer (non-malignant or malignant). 8. presence or history (including suspected diagnosis) of breast cancer. 9. presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g. endometrial cancer). 10. patients with endometrial hyperplasia. 11. patients with severe hypoxemia at risk of endotracheal intubation. 12. immunocompromised patients 13. history of stroke, acute coronary syndromes, or angina pectoris. 14. presence or history of arterial or venous thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli). 15. patients with any condition, including findings in the patients' medical history or in the screening study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation, including patients with suspected genital cancer or suspected breast cancer and patients with increased risk of development of venous thrombosis/thromboembolia for reasons other than covid-19 disease. 16. use of zanamivir or oseltamivir within 1 week prior to randomization. 17. patients who have received prior investigational or off-label agents for covid-19. (note: use of antivirals and corticosteroids is allowed if part of standard of care). 18. using methyldopa or clonidine containing antihypertensive medication. 19. hypersensitivity to the active substance of the study drug or any other components of the study drug.

1. males currently receiving estrogen-based hormonal therapy. 2. current participation in another interventional clinical trial. 3. ventilated and/or in icu. 4. any unexplained abnormal bleeding including, but not limited to, vaginal bleeding. 5. diagnosed protein c, protein s or antithrombin iii deficiency or any other known inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia, anti-phospholipid antibodies). 6. renal impairment (glomerular filtration rate [gfr] <30 ml/min/1.73 m²). 7. presence or history of severe liver disease or liver cancer (non-malignant or malignant). 8. presence or history (including suspected diagnosis) of breast cancer. 9. presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g. endometrial cancer). 10. patients with endometrial hyperplasia. 11. patients with severe hypoxemia at risk of endotracheal intubation. 12. immunocompromised patients 13. history of stroke, acute coronary syndromes, or angina pectoris. 14. presence, history, or patients at risk of development of arterial or venous thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli). 15. patients with any condition, including findings in the patients' medical history or in the screening study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation, including patients with suspected genital cancer or suspected breast cancer. 16. use of zanamivir or oseltamivir within 1 week prior to randomization. 17. vaccinations within 30 days of screening. 18. patients who have received prior investigational or off-label agents for covid-19. (note: use of antivirals and corticosteroids is allowed if part of standard of care). 19. using methyldopa or clonidine containing antihypertensive medication. 20. hypersensitivity to the active substance of the study drug or any other components of the study drug.

1. males currently receiving estrogen-based hormonal therapy. 2. current participation in another interventional clinical trial. 3. ventilated and/or in icu. 4. any unexplained abnormal bleeding including, but not limited to, vaginal bleeding. 5. diagnosed protein c, protein s or antithrombin iii deficiency or any other known inherited or acquired thrombophilic abnormalities (e.g. hyperhomocysteinemia, anti-phospholipid antibodies). 6. renal impairment (glomerular filtration rate [gfr] <30 ml/min/1.73 m²). 7. presence or history of severe liver disease or liver cancer (non-malignant or malignant). 8. presence or history (including suspected diagnosis) of breast cancer. 9. presence or history (including suspected diagnosis) of estrogen-sensitive tumors (e.g. endometrial cancer). 10. patients with endometrial hyperplasia. 11. patients with severe hypoxemia at risk of endotracheal intubation. 12. immunocompromised patients 13. history of stroke, acute coronary syndromes, or angina pectoris. 14. presence, history, or patients at risk of development of arterial or venous thrombosis/thrombembolia (including deep vein thrombosis and pulmonary emboli). 15. patients with any condition, including findings in the patients' medical history or in the screening study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation, including patients with suspected genital cancer or suspected breast cancer. 16. use of zanamivir or oseltamivir within 1 week prior to randomization. 17. vaccinations within 30 days of screening. 18. patients who have received prior investigational or off-label agents for covid-19. (note: use of antivirals and corticosteroids is allowed if part of standard of care). 19. using methyldopa or clonidine containing antihypertensive medication. 20. hypersensitivity to the active substance of the study drug or any other components of the study drug.